The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 03, 2006
Filed:
Nov. 03, 2000
Mark Robert Barvian, Ann Arbor, MI (US);
Ellen Myra Dobrusin, Ann Arbor, MI (US);
James Stanley Kaltenbronn, Ann Arbor, MI (US);
Peter L. Toogood, Ann Arbor, MI (US);
Roy Thomas Winters, Pinckney, MI (US);
Inderjit S. Sidhu, Edmonton, CA;
Rajeshwar Singh, Edmonton, CA;
Yadagiri Bathini, Alberta, CA;
Ronald George Micetich, Sherwood Park, CA;
Mark Robert Barvian, Ann Arbor, MI (US);
Ellen Myra Dobrusin, Ann Arbor, MI (US);
James Stanley Kaltenbronn, Ann Arbor, MI (US);
Peter L. Toogood, Ann Arbor, MI (US);
Roy Thomas Winters, Pinckney, MI (US);
Inderjit S. Sidhu, Edmonton, CA;
Rajeshwar Singh, Edmonton, CA;
Yadagiri Bathini, Alberta, CA;
Ronald George Micetich, Sherwood Park, CA;
Warner-Lambert Company, Morris Plains, NJ (US);
Abstract
This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-7-(alkyl)oxy-8-alkylquinazolines and 8-alkyl-2-arylamino-quinazoline 2,7-diamines that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provide useful intermediates generated during the production of the quinazoline compounds.